

ASX Announcement

14 September 2026

Date of Annual General Meeting and Closing Date for Director Nominations

Genetic Signatures Limited (ASX: GSS) (GSS or the Company) advises in accordance with ASX Listing Rule 3.13.1, that its 2026 Annual General Meeting (**AGM**) will be held on Monday 16 November 2026.

An item of business at the AGM will be the re-election of directors.

In accordance with the Company's Constitution, the closing date for receipt of nominations from persons wishing to be considered for election as a director is Monday 21 September 2026.

Any nominations must be received at the Company's registered office no later than 5:00pm AEST on Monday 21 September 2026.

Further details regarding the AGM will be provided in the Notice of Meeting, which will be released to the ASX and made available to shareholders in due course.

– END –

Announcement authorised by Genetic Signatures Limited's Board of Directors.

For further information, see our website (www.geneticsignatures.com) or contact us:

Mike Aicher

Chair, Genetic Signatures Limited
mike.aicher@geneticsignatures.com
T: +61 (0)2 9870 7580

Maria Halasz

CEO, Genetic Signatures Limited
maria.halasz@geneticsignatures.com
T: +61 (0)2 9870 7580

About Genetic Signatures

Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. Genetic Signatures' proprietary 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.